NIH Reluctant To “March In”: Collins Suggests Authority Not Intended To Address Pricing Concerns
This article was originally published in RPM Report
Legislators are urging the National Institutes of Health to use intellectual property levers to put pressure on prescription drug pricing. NIH has historically been reluctant to play the role of the price police – and it still is.
Register for our free email digests: